A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthmatic patients.
Phase of Trial: Phase II
Latest Information Update: 04 May 2015
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2012 Planned number of patients changed from 24 to 28 as reported by European Clinical Trials Database record.
- 01 Sep 2010 Actual patient number is 28 as reported by ClinicalTrials.gov.